Cargando…
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large numb...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/ https://www.ncbi.nlm.nih.gov/pubmed/31179334 http://dx.doi.org/10.1155/2019/9056417 |
_version_ | 1783416959603310592 |
---|---|
author | Signorelli, Diego Giannatempo, Patrizia Grazia, Giulia Aiello, Marco Maria Bertolini, Federica Mirabile, Aurora Buti, Sebastiano Vasile, Enrico Scotti, Vieri Pisapia, Pasquale Cona, Maria Silvia Rolfo, Christian Malapelle, Umberto Group, Immune-Oncology YOUNG |
author_facet | Signorelli, Diego Giannatempo, Patrizia Grazia, Giulia Aiello, Marco Maria Bertolini, Federica Mirabile, Aurora Buti, Sebastiano Vasile, Enrico Scotti, Vieri Pisapia, Pasquale Cona, Maria Silvia Rolfo, Christian Malapelle, Umberto Group, Immune-Oncology YOUNG |
author_sort | Signorelli, Diego |
collection | PubMed |
description | Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection. |
format | Online Article Text |
id | pubmed-6507101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-65071012019-06-09 Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker Signorelli, Diego Giannatempo, Patrizia Grazia, Giulia Aiello, Marco Maria Bertolini, Federica Mirabile, Aurora Buti, Sebastiano Vasile, Enrico Scotti, Vieri Pisapia, Pasquale Cona, Maria Silvia Rolfo, Christian Malapelle, Umberto Group, Immune-Oncology YOUNG Biomed Res Int Review Article Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection. Hindawi 2019-04-24 /pmc/articles/PMC6507101/ /pubmed/31179334 http://dx.doi.org/10.1155/2019/9056417 Text en Copyright © 2019 Diego Signorelli et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Signorelli, Diego Giannatempo, Patrizia Grazia, Giulia Aiello, Marco Maria Bertolini, Federica Mirabile, Aurora Buti, Sebastiano Vasile, Enrico Scotti, Vieri Pisapia, Pasquale Cona, Maria Silvia Rolfo, Christian Malapelle, Umberto Group, Immune-Oncology YOUNG Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title_full | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title_fullStr | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title_full_unstemmed | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title_short | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker |
title_sort | patients selection for immunotherapy in solid tumors: overcome the naïve vision of a single biomarker |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/ https://www.ncbi.nlm.nih.gov/pubmed/31179334 http://dx.doi.org/10.1155/2019/9056417 |
work_keys_str_mv | AT signorellidiego patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT giannatempopatrizia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT graziagiulia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT aiellomarcomaria patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT bertolinifederica patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT mirabileaurora patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT butisebastiano patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT vasileenrico patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT scottivieri patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT pisapiapasquale patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT conamariasilvia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT rolfochristian patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT malapelleumberto patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker AT groupimmuneoncologyyoung patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker |